Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960082 | 0.81 | HTT (0.57) | HTTALDH1A1TOP1PKMPOLB | |
| SCHEMBL16614391 | 0.75 | ADORA3 (0.59) | ALDH1A1TOP1KMT2ALMNAMAPK1 | |
| SCHEMBL21959257 | 0.75 | TOP1 (0.62) | HTTALDH1A1TOP1KMT2ALMNA | |
| SCHEMBL12192031 | 0.71 | ALDH1A1 (0.49) | HTTALDH1A1TOP1KMT2ALMNA | |
| SCHEMBL27280748 | 0.71 | ALDH1A1 (0.58) | ALDH1A1KMT2ALMNAMAPK1L3MBTL1 | |
| SCHEMBL24678433 | 0.71 | ALDH1A1 (0.51) | ALDH1A1TOP1KMT2ALMNAMAPK1 | |
| SCHEMBL16306922 | 0.71 | HTT (0.67) | HTTALDH1A1PKMPOLBHSP90AA1 | |
| SCHEMBL16295827 | 0.71 | HTT (0.67) | HTTALDH1A1PKMPOLBHSP90AA1 | |
| SCHEMBL16295828 | 0.71 | HTT (0.67) | HTTALDH1A1PKMPOLBHSP90AA1 | |
| SCHEMBL4623958 | 0.70 | EPHX2 (0.60) | POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123197-A1 | METHOD OF MAKING A CROSS METATHESIS PRODUCT | NATIONAL SCIENCE FOUNDATION | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123197-A1 | METHOD OF MAKING A CROSS METATHESIS PRODUCT | DUOX2, DUOX1, RNF168 | HTT 4420/4885ALDH1A1 1487/4885MAOB 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.